Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in ...
Adjuvant abemaciclib combined with endocrine therapy (ET) has demonstrated a statistically significant and clinically ...
A combination of two supplements — resveratrol and copper — reduced the aggressiveness of tumors in glioblastoma, a type of ...
Prediction: IoT Analytics expects 2026 to bring wider adoption of AI-aware EDA flows and off-the-shelf AI IP subsystems in IoT chip development. These tools and IP blocks will reduce design complexity ...
Zacks Investment Research on MSN
What awaits these 4 biotech stocks that more than doubled in 2025
After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a ...
Takeda Canada Inc. (“Takeda”) is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...
Wi-Fi 7 is no longer just a mere, abstract concept, but rather, the lubricant to help corporations apply advanced ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to ...
As part of the PDAOAI initiative, Oncotelic has curated a comprehensive TGF-β literature corpus comprising more than 125,000 ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
The government is committed to strengthening diaspora-friendly policies and expanding opportunities for collaboration as part of the country’s reset agenda, the Vice- President, Professor Naana Jane ...
Novartis' phase III PREVENT trial of Cosentyx in patients with nr-axSpA meets primary endpoint: Basel Wednesday, November 13, 2019, 09:00 Hrs [IST] Novartis, a leader in rheumatol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback